Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 1
2015 1
2016 2
2017 1
2020 4
2021 4
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, Wick W, Chinot O, Ducray F, Roth P, McDonald K, Hau P, Hottinger AF, Reijneveld J, Schnell O, Marosi C, Glantz M, Darlix A, Lombardi G, Krex D, Glas M, Reardon DA, van den Bent M, Lefranc F, Herrlinger U, Razis E, Carpentier AF, Phillips S, Rudà R, Wick A, Tabouret E, Meyronet D, Maurage CA, Rushing E, Rapkins R, Bumes E, Hegi M, Weyerbrock A, Aregawi D, Gonzalez-Gomez C, Pellerino A, Klein M, Preusser M, Bendszus M, Golfinopoulos V, von Deimling A, Gorlia T, Wen PY, Reifenberger G, Weller M. Hertler C, et al. Among authors: bumes e. Eur J Cancer. 2023 Aug;189:112913. doi: 10.1016/j.ejca.2023.05.002. Epub 2023 May 8. Eur J Cancer. 2023. PMID: 37277265 Free article.
Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre.
Scheiter A, Hierl F, Lüke F, Keil F, Heudobler D, Einhell S, Klier-Richter M, Konstandin NP, Weber F, Scheiter A, Kandulski A, Schlosser S, Cosma LS, Tews H, Weiss ARR, Grube M, Bumes E, Hau P, Proescholdt M, Steger F, Troeger A, Haferkamp S, Reibenspies LE, Schnabel MJ, Schulz C, Drexler K, Hatzipanagiotou ME, Seitz S, Klinkhammer-Schalke M, Unberath P, Calvisi DF, Pukrop T, Dietmaier W, Evert M, Utpatel K. Scheiter A, et al. Among authors: bumes e. Br J Cancer. 2023 Apr;128(6):1134-1147. doi: 10.1038/s41416-022-02120-x. Epub 2022 Dec 26. Br J Cancer. 2023. PMID: 36572733 Free PMC article.
Breakouts-A Radiological Sign of Poor Prognosis in Patients With Brain Metastases.
Blazquez R, Proescholdt MA, Klauser M, Schebesch KM, Doenitz C, Heudobler D, Stange L, Riemenschneider MJ, Bumes E, Rosengarth K, Schicho A, Schmidt NO, Brawanski A, Pukrop T, Wendl C. Blazquez R, et al. Among authors: bumes e. Front Oncol. 2022 Apr 4;12:849880. doi: 10.3389/fonc.2022.849880. eCollection 2022. Front Oncol. 2022. PMID: 35444944 Free PMC article.
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma.
Lazaridis L, Bumes E, Cäcilia Spille D, Schulz T, Heider S, Agkatsev S, Schmidt T, Blau T, Oster C, Feldheim J, Stummer W, Kessler AF, Seidel C, Grauer O, Hau P, Sure U, Keyvani K, Herrlinger U, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Breuer S, Hattingen E, Scheffler B, Kebir S, Glas M. Lazaridis L, et al. Among authors: bumes e. Neurooncol Adv. 2022 Aug 24;4(1):vdac137. doi: 10.1093/noajnl/vdac137. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36284931 Free PMC article.
23 results